Kataoka Hideki, Tanaka Masamitsu, Kanamori Masao, Yoshii Shigeto, Ihara Megumi, Wang You-Jie, Song Jian-Ping, Li Zhong-You, Arai Hajime, Otsuki Yoshiro, Kobayashi Toshihiko, Konno Hiroyuki, Hanai Hiroyuki, Sugimura Haruhiko
First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
J Cancer Res Clin Oncol. 2002 Jul;128(7):343-8. doi: 10.1007/s00432-002-0355-0. Epub 2002 Jun 26.
We have previously reported that EPHB2 is overexpressed in gastric cancer; however, the expression profiles of its ligands, EFNB1 and EFNB2, are unknown. This study was designed to investigate the expression of EPHB2 and its ligands, EFNB1 and EFNB2, in human gastric cancer.
Semi-quantitative RT-PCR using (32)P was performed on human gastric cancer tissues and corresponding normal tissues (29 gastric cancer patients).
EPHB2 was more highly expressed in tumor tissues than in normal tissues in 21 out of 29 (72.4%), in gastric cancer patients ( P = 0.01); EFNB1 and EFNB2 were highly expressed in 21 out of 29 (72.4%) ( P = 0.037) and 14 out of 29 (48.3%) patients, respectively. The overexpression of EPHB2 was frequently detected in both well-differentiated adenocarcinoma and poorly differentiated adenocarcinoma [10/13 (76.9%) and 9/14 (64.3%), respectively]. On the other hand, the overexpression of EFNB1 was more frequently detected in poorly differentiated adenocarcinoma than in well-differentiated adenocarcinoma [12/14 (85.7%) and 7/13 (53.8%), respectively. P =0.027]. Elevated levels of EPHB2 and EFNB1 were detected in substantial subsets of early gastric cancers. Genomic alterations to these three genes in gastric cancer specimens were either not found or rarely found except for several rare variations of EPHB2.
These findings suggest that not only the expression of EPHB2, but the expression of its ligand EFNB1 may have some relation with the oncogenesis of gastric cancer.
我们之前报道过EPHB2在胃癌中过表达；然而，其配体EFNB1和EFNB2的表达谱尚不清楚。本研究旨在调查EPHB2及其配体EFNB1和EFNB2在人胃癌中的表达情况。
对人胃癌组织及相应正常组织（29例胃癌患者）进行使用³²P的半定量逆转录聚合酶链反应（RT-PCR）。
29例胃癌患者中，21例（72.4%）肿瘤组织中EPHB2的表达高于正常组织（P = 0.01）；EFNB1和EFNB2分别在21例（72.4%）（P = 0.037）和14例（48.3%）患者中高表达。EPHB2的过表达在高分化腺癌和低分化腺癌中均经常被检测到[分别为10/13（76.9%）和9/14（64.3%）]。另一方面，EFNB1的过表达在低分化腺癌中比在高分化腺癌中更频繁地被检测到[分别为12/14（85.7%）和7/13（53.8%）。P = 0.027]。在相当一部分早期胃癌中检测到EPHB2和EFNB1水平升高。除了EPHB2的一些罕见变异外，在胃癌标本中未发现或很少发现这三个基因的基因组改变。
这些发现表明，不仅EPHB2 的表达，而且其配体EFNB1的表达可能与胃癌的发生有关。
